Simplify Logo

Full-Time

Postdoctoral Fellow

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

201-500 employees

Develops drugs for muscle function improvement

Hardware
Biotechnology
Healthcare

Compensation Overview

$80k - $85kAnnually

Entry

San Bruno, CA, USA

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in biochemistry, bioengineering, cell/molecular biology, physiology, or related field
  • Expertise in one or more of the following: primary and mammalian cell culture systems, in vivo models of heart failure and/or skeletal muscle diseases, RNA-seq, proteomics, bioinformatics analysis
  • Well-articulated career goals in research (biotech or academia)
  • Track record for research excellence, independent critical thinking, and the ability to design, execute, and interpret experiments as demonstrated by high quality publications, presentations, fellowship, and grants
  • Enthusiasm for working in a team-based, multi-disciplinary environment, paired with excellent verbal and written communication skills
  • Clear commitment to a rigorous 2-year research and enrichment program
Responsibilities
  • The candidate will be involved in designing and executing an independent research project focused on cardiac or skeletal muscle biology. The fellow will work collaboratively with their research mentor with the goal of generating a high impact publication.
  • The candidate will play an integral role in championing new projects and ideas for discovery of novel targets and therapeutics, and will conduct research both working independently and in a collaborative team-based setting
  • As a key team member, the candidate will provide regular project updates and progress in small and large group settings, and provide scientific and technical expertise to advance programs

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.